


GioTag study: concept



GioTag: design and results

Patients (n=203): received first-line afatinib followed by osimertinib after developing T790M-mediated resistance

N=203 patients with EGFR+ NSCLC

Recruited from 10 countries


15% of patients had ECOG PS of ≥ 2

10% had stable brain mets

59% Caucasian
25% Asian
9% African American

Data from electronic health records:
62%

Manual chart review:
38%



ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR+: EGFR mutation-positive; OS: overall survival; TTF: time to treatment failure
*Based on an interim update analysis; only electronic health record data have been updated since the primary analysis (Hochmair et al. Future Oncol 2018;14:2861-74). Final analysis due in 2020.